Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Ray McDermott et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsDirk Strumberg, Brian Schwartz, Jeffrey W. Clark et al.|The Oncologist|2007Cited by 418
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Sara Lonardi et al.|Annals of Oncology|2022Cited by 253
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug ResistancePashalina Kehagias, Alain Hendlisz|Cells|2022Cited by 13